ITM Enters Cooperation Agreement with Paul Scherrer Institute (PSI) for Co-Development and Upscaled Manufacturing of Terbium-161 for Theranostic Application in Cancer
April 27, 2023 05:00 ET
|
ITM Isotope Technologies Munich SE
Enhancement of ITM’s development and manufacturing activities strengthens ITM’s position as a pioneer and leader in Targeted Radionuclide Therapy (TRT) Garching / Munich, April 27, 2023 – ITM...
ITM Appoints Roger Estafanos as U.S. General Manager and Expands Presence with Opening of U.S. Headquarters in Princeton, New Jersey
April 17, 2023 08:03 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich and Princeton, NJ, April 17, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical theranostics company, today announced that the company has opened its U.S....
Precision Oncology Market Predicted to Garner US$ 202.5 Billion by 2032, At CAGR 9.8%
April 11, 2023 10:16 ET
|
Market.Us
New York, April 11, 2023 (GLOBE NEWSWIRE) -- According to Market.us, The Precision Oncology Market was worth US$ 81.37 billion in 2022 and is expected to reach US$ 202.5 billion by 2032 with a CAGR...
Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
April 11, 2023 08:30 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., April 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced details relating to eight...
ITM, Helmholtz Munich and University Hospital Münster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma
March 13, 2023 06:13 ET
|
ITM Isotope Technologies Munich SE
Garching/Munich, Munich and Münster, Germany, March 13, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, Helmholtz Munich and the Departments of...
Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
February 09, 2023 09:05 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will...
Global Genomic Cancer Panel and Profiling Markets, 2023-2027 - Next Generation Sequencing Fuels a Revolution
February 09, 2023 04:48 ET
|
Research and Markets
Dublin, Feb. 09, 2023 (GLOBE NEWSWIRE) -- The "Genomic Cancer Panel and Profiling Markets by Cancer, by Application, by Tissue and by Gene Type with Screening Potential Market Size, Customized...
NGS-Based RNA-Sequencing Global Market Report 2022: Featuring Illumina, Thermo Fischer Scientific, Oxford Nanopore, Agilent Technologies & BGI
January 03, 2023 07:18 ET
|
Research and Markets
Dublin, Jan. 03, 2023 (GLOBE NEWSWIRE) -- The "NGS-Based RNA-Sequencing Global Market Report 2022: Ukraine-Russia War Impact" report has been added to ResearchAndMarkets.com's offering.The global...
Modifi Bio Announces Scientific Advisory Board
December 13, 2022 08:30 ET
|
Modifi Biosciences
NEW HAVEN, Conn., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Modifi Biosciences, a leader in DNA modification as a novel approach to target cancer, today announced its Scientific Advisory Board, with the...
Breast Cancer Canada announces $500K in new grant funding
December 01, 2022 13:58 ET
|
Breast Cancer Canada
SARNIA, Ontario, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Breast Cancer Canada today announced a call for proposals for their 2023 Precision Oncology Research Grants which will award $500,000 in new...